Pharnext Sa : Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A -November 23, 2023 at 02:35 am EST

PARIS, France, November 23, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

Related Keywords

France ,United States ,Paris ,France General ,Hugo Brugi ,Fabreguettes Leib ,Anne Charlotte Dudicourt ,Euronext Growth Stock Exchange ,Financial Press Relations ,Overall Neuropathy Limitations Scale ,Open Label Extension ,Charcot Marie Tooth Disease Type ,Global Tech Opportunities ,Announces First Patient Enrolled ,Pivotal Phase ,Markets ,